Application 021351
- Type
- NDA
- Sponsor
- ALLERGAN
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 002 | OXYTROL | OXYBUTYNIN | FILM, EXTENDED RELEASE;TRANSDERMAL | 3.9MG/24HR | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021351-002 | OXYTROL | OXYBUTYNIN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021351-002 | OXYTROL | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N021351-002 | OXYTROL | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | N021351-002 | OXYTROL | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N021351-002 | OXYTROL | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N021351-002 | OXYTROL | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2003-02-26 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | 74a2ff9319b5… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 6743441 | 2020-04-26 | U-318 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 7081249 | 2020-04-26 | U-318 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 7081250 | 2020-04-26 | U-318 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 7081251 | 2020-04-26 | U-318 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 7081252 | 2020-04-26 | U-318 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021351-002 | 7179483 | 2020-04-26 | U-318 | Drug substance, Drug product | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OXYTROL | OXYBUTYNIN | Allergan, Inc. | 20dee37f-1412-44ed-9e8b-f4379ce23eb0 | 2024-05-29 | Warnings, Adverse reactions | 021351 NDA021351 0023-6153 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
Documents#
| Document | Submission type | Date |
|---|---|---|
| 78601 | SUPPL | 2024-09-06 |
| 78578 | SUPPL | 2024-05-30 |
| 50221 | SUPPL | 2017-10-30 |
| 50220 | SUPPL | 2017-10-30 |
| 50172 | SUPPL | 2017-10-25 |
| 50171 | SUPPL | 2017-10-25 |
| 15259 | SUPPL | 2015-07-13 |
| 5132 | SUPPL | 2015-07-13 |
| 36733 | SUPPL | 2012-10-12 |
| 27565 | SUPPL | 2012-10-12 |
| 15258 | SUPPL | 2012-10-12 |
| 5131 | SUPPL | 2012-10-12 |
| 5130 | SUPPL | 2011-02-03 |
| 36732 | SUPPL | 2011-01-31 |
| 5129 | SUPPL | 2006-07-13 |
| 36731 | SUPPL | 2006-07-07 |
| 42116 | ORIG | 2005-04-08 |
| 27564 | ORIG | 2003-03-10 |
| 15257 | ORIG | 2003-02-26 |